Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX

Monaco Asset Management SAM purchased a new position in shares of Nkarta, Inc. (NASDAQ:NKTX – Free Report) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 2,373,400 shares of the company’s stock, valued at approximately $6,717,000. Nkarta comprises about 0.5% of Monaco Asset Management SAM’s portfolio, making the stock its 13th biggest position.

A number of other hedge funds have also recently modified their holdings of the business. GSK plc purchased a new stake in shares of Nkarta in the 4th quarter worth $5,829,000. Jane Street Group LLC lifted its position in Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after purchasing an additional 852,559 shares in the last quarter. Millennium Management LLC bought a new stake in Nkarta during the third quarter valued at about $1,549,000. Renaissance Technologies LLC grew its holdings in Nkarta by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,702,022 shares of the company’s stock valued at $3,149,000 after purchasing an additional 556,945 shares during the period. Finally, AQR Capital Management LLC increased its position in Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock worth $1,237,000 after buying an additional 504,272 shares in the last quarter. Institutional investors own 80.54% of the company’s stock.

Get Nkarta alerts:

Nkarta News Roundup

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article

Analyst Ratings Changes

Several research firms have recently commented on NKTX. Evercore set a $9.00 price objective on Nkarta in a research note on Monday, May 18th. Wall Street Zen cut shares of Nkarta from a “sell” rating to a “strong sell” rating in a research note on Saturday. Stifel Nicolaus decreased their target price on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Nkarta in a report on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nkarta currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.20.

Check Out Our Latest Report on NKTX

Nkarta Stock Performance

Shares of Nkarta stock opened at $2.33 on Monday. The stock has a market cap of $166.87 million, a price-to-earnings ratio of -1.48 and a beta of 0.93. The stock has a 50 day moving average price of $2.64 and a 200-day moving average price of $2.58. Nkarta, Inc. has a one year low of $1.70 and a one year high of $3.72.

Nkarta (NASDAQ:NKTX – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.18). Sell-side analysts predict that Nkarta, Inc. will post -1.54 earnings per share for the current fiscal year.

Nkarta Company Profile

(Free Report)

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.

Featured Stories

• Five stocks we like better than Nkarta
• The Metals Company’s Big Bet Now Comes Down to a License
• OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
• Meta and Tesla Are Rebounding From Oversold Levels—Now What?
• AMG’s Alternatives Boom Powers Record Growth

Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX – Free Report).

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.